Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 6, 2010Arthritis & RheumatismOpen Access

Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series

View Full Paper
Ask AI
Bookmark
Share

Authors

PNPeter A. NigrovićBrigham and Women's HospitalMMMelissa L. MannionChildren's of AlabamaFPFemke H. M. PrinceBrigham and Women's Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nigrović et al. (2010) studied this question.

synapsesocial.com/papers/6a1981e1ff42a97fac5836c2https://doi.org/10.1002/art.30128
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Juvenile Rheumatoid Arthritis: A Review1972 · 144 citations
  2. 2Juvenile Chronic Arthritis1987 · 32 citations
  3. 3Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis2009 · 110 citations
  4. 4Combination Therapy of Abatacept and Anakinra in Children with Refractory Systemic Juvenile Idiopathic Arthritis: A Retrospective Case Series: Table 1.2011 · 83 citations